Huilun Pharma

Shanghai Huilun Pharmaceutical Co., Ltd. is an innovative pharmaceutical enterprise. After years of development, we have built an integrated operational system spanning from research and development, production to commercialization, with the core strategic focus on developing innovative drugs for critical diseases and severe conditions. Since its establishment, we have concentrated on areas such as immune inflammation, pain management, cancer treatment, and chronic diseases. With deep expertise, we have advanced four Class I innovative drugs and three Class II improved new drugs into clinical trials. To date, we have commercially launched more than ten drugs in China, including Xivilest sodium (brand name: Cytopin®), the only domestically produced drug approved in China. We are committed to developing safe, effective, and highly clinically valuable medicines to continuously address unmet clinical needs. Leveraging our proprietary technology platforms, integrated manufacturing systems, and nationwide sales network in China, we provide a solid foundation for the research and commercialization of innovative drugs. The stable cash flow generated by marketed products effectively hedges the risks associated with new drug development while ensuring the company maintains robust commercial resilience as it advances its innovation strategy.